Synthetic Bio Firm Gen9 Raises $395K | GenomeWeb

NEW YORK (GenomeWeb News) – Synthetic biology firm Gen9 has raised $395,000 toward a $2 million round, the company said in a regulatory document filed Tuesday.

In its Form D filed with the US Securities and Exchange Commission, the Cambridge, Mass.-based firm said that the funds raised were in the form of debt. Kevin Munnelly, its president and chief business officer, told GenomeWeb Daily News in an e-mail today that proceeds will be used to commercialize the company's products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.